Literature DB >> 28775602

LUPUS NEPHRITIS-A CRITICAL ANALYSIS OF 17 PATIENTS.

P K Prasher1, P P Varma2, K V Baliga3, S S Uppal4, J S Saini5.   

Abstract

Over a 3 year period from June 94 to June 97, out of 28 patients of systemic lupus, 17 were diagnosed as renal lupus. Demographic data showed 12 females and 5 males, mean age being 32.2 years (range 12 to 54 years). Mean time gap between presentation and definitive diagnosis was 32.4 days (7 days to 5 years). 2 patients (11.76%) presented renal lupus, one (5.88%) with acute interstitial lung disease and the remaining had the usual systemic manifestations of lupus. Anti dsDNA antibodies were positive in all patients while ANA was negative in 3 cases. Renal involvement consisted of rapidly progressive glomerulonephritis in 2 patients (11.76%), nephrotic syndrome in 4 (23.52%) and non nephrotic range proteinuria in 11 (64.70%) patients. Mean serum creatinine at presentation was 2.4mg/dl (0.8mg/dl to 8.9 mg/dl). Three patients were dialysis dependent. Renal histology on light microscopy comprised of class II lesions in one (5.88%), class III in 4 (23.52%), class IV in 11 (64.70%-including one with crescents) and class V in one (5.88%) patient. All patients with advanced class III/IV lesions were treated with corticosteroids and cyclophosphamide pulses. Except one patient who died of pyopericardium all others improved and their serum creatinine stabilised around 2.3 mg/dl (0.8 to 4.6 mg/dl). The study highlights the importance of early diagnosis and aggressive management in this potentially treatable disease.

Entities:  

Keywords:  Lupus nephritis; Pulse cyclophosphamide

Year:  2017        PMID: 28775602      PMCID: PMC5531826          DOI: 10.1016/S0377-1237(17)30267-8

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

Review 1.  Immunosuppressive drug therapy in lupus nephritis.

Authors:  J V Donadio; R J Glassock
Journal:  Am J Kidney Dis       Date:  1993-03       Impact factor: 8.860

Review 2.  Lupus nephritis: lessons from the path lab.

Authors:  M Kashgarian
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

3.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; S P Lan; R D Rohde; J M Lachin
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

4.  Silent diffuse lupus nephritis: long-term follow-up.

Authors:  D J Leehey; A I Katz; A H Azaran; A J Aronson; B H Spargo
Journal:  Am J Kidney Dis       Date:  1982-07       Impact factor: 8.860

5.  Focal proliferative lupus nephritis. A clinicopathologic study using the W.H.O. classification.

Authors:  A B Magil; H S Ballon; A Rae
Journal:  Am J Med       Date:  1982-04       Impact factor: 4.965

6.  Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients.

Authors:  H C Nossent; S C Henzen-Logmans; T M Vroom; J H Berden; T J Swaak
Journal:  Arthritis Rheum       Date:  1990-07

7.  Predictors of one year outcome in lupus nephritis: the importance of renal biopsy.

Authors:  J M Esdaile; W Federgreen; H Quintal; S Suissa; J P Hayslett; M Kashgarian
Journal:  Q J Med       Date:  1991-11

8.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome.

Authors:  H A Austin; L R Muenz; K M Joyce; T T Antonovych; J E Balow
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

9.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only.

Authors:  A D Steinberg; S C Steinberg
Journal:  Arthritis Rheum       Date:  1991-08

10.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.

Authors:  W J McCune; J Golbus; W Zeldes; P Bohlke; R Dunne; D A Fox
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.